Angelica Welch

Articles

Choueiri Reflects on Recent RCC Advances

July 26th 2018

Toni K. Choueiri, MD, discusses some of the most significant data presented thus far in 2018 for the treatment of patients with renal cell carcinoma.

Langer Highlights the Impact of Chemoimmunotherapy in NSCLC

July 24th 2018

Although impressive single-agent data have been seen with agents such as pembrolizumab (Keytruda) versus chemotherapy in a high–PD-L1 population, the combination of PD-L1 inhibitors and chemotherapy may prove to be beneficial in a broader group of patients.

Lonial Lays Out Optimal Sequence Strategies for Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

The Future of Myeloma Induction May Be Quadruplets

July 19th 2018

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

Kahl Shares Antibody-Drug Conjugate Updates in Lymphoma

July 18th 2018

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

Ramalingam Reflects on Recent Advances in SCLC

July 17th 2018

Suresh A. Ramalingam, MD, reflects on recent data in small cell lung cancer and what is on the horizon in the landscape.

Maintenance Rituximab Linked to Improved Outcomes in MCL

July 16th 2018

Talal Hilal, MB, BCh, discusses the findings of a meta-analysis of rituximab maintenance for patients with mantle cell lymphoma (MCL), and the approach to maintenance therapy in patients with MCL.

Lead Author Reflects on LILAC Study of Trastuzumab Biosimilar ABP 980

July 13th 2018

Hans-Christian Kolberg, MD, discusses ABP 980 and the future of biosimilars in oncology.

Galsky Discusses Ongoing Combination Immunotherapy Trials in Bladder Cancer

July 13th 2018

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.

Yu Shares Insight on Recent Advances in Castration-Sensitive Prostate Cancer

July 10th 2018

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

Expert Sheds Light on Adjuvant Treatment of HR+ Breast Cancer

July 9th 2018

Michael A. Savin, MD, shares his insight on adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer.

CDK4/6 Inhibitors Continue to Offer Hope in Breast Cancer

July 6th 2018

Jacqueline Vuky, MD, discusses the management of metastatic disease and CDK4/6 inhibitors in breast cancer.

Pembrolizumab Plus Lenvatinib Active in Endometrial Cancer

July 6th 2018

Vicky Makker, MD, discusses the updated phase Ib/II results of the combination of pembrolizumab and lenvatinib and the future of endometrial cancer treatment.

Expert Discusses Daratumumab Developments in Myeloma

July 6th 2018

Ajai Chari, MD, discusses the addition of daratumumab to carfilzomib and dexamethasone, as well as the potential impact of subcutaneous daratumumab in the treatment of patients with myeloma.

Garassino Highlights ASCO NSCLC Findings and Looks to the Future

July 3rd 2018

Marina Chiara Garassino, MD, reflects on the first-line approval of osimertinib, recent data with durvalumab, and the promise for combination chemoimmunotherapy in patients with non–small cell lung cancer.

Addressing PARP Inhibitor Resistance in Ovarian Cancer

July 2nd 2018

Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

Expert Provides Clarity on Treatment of Advanced HCC

June 28th 2018

Mitesh J. Borad, MD, discusses liver-directed therapies, systemic therapy, and the management of liver cancer.

Expert Discusses Potential Breakthroughs in ROS1+ and BRAF+ NSCLC

June 25th 2018

Sai-Hong Ignatius Ou, MD, PhD, discusses the current landscapes of ROS1-positive and BRAF-mutant non–small cell lung cancer.

Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC

June 22nd 2018

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

Expert Discusses Venetoclax Potential in MCL

June 22nd 2018

Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.